Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60


Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis.

Boedigheimer MJ, Martin DA, Amoura Z, Sánchez-Guerrero J, Romero-Diaz J, Kivitz A, Aranow C, Chan TM, Chong YB, Chiu K, Wang C, Sohn W, Arnold GE, Damore MA, Welcher AA, Sullivan BA, Kotzin BL, Chung JB.

Lupus Sci Med. 2017 Sep 14;4(1):e000226. doi: 10.1136/lupus-2017-000226. eCollection 2017.


Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-γ Antibody, in Patients With Discoid Lupus Erythematosus.

Werth VP, Fiorentino D, Sullivan BA, Boedigheimer MJ, Chiu K, Wang C, Arnold GE, Damore MA, Bigler J, Welcher AA, Russell CB, Martin DA, Chung JB.

Arthritis Rheumatol. 2017 May;69(5):1028-1034. doi: 10.1002/art.40052. Epub 2017 Mar 31.


A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U-BIOPRED Cohorts.

Bigler J, Boedigheimer M, Schofield JPR, Skipp PJ, Corfield J, Rowe A, Sousa AR, Timour M, Twehues L, Hu X, Roberts G, Welcher AA, Yu W, Lefaudeux D, Meulder B, Auffray C, Chung KF, Adcock IM, Sterk PJ, Djukanović R; U-BIOPRED Study Group ‖.

Am J Respir Crit Care Med. 2017 May 15;195(10):1311-1320. doi: 10.1164/rccm.201604-0866OC.


Blockade of interferon-γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus.

Welcher AA, Boedigheimer M, Kivitz AJ, Amoura Z, Buyon J, Rudinskaya A, Latinis K, Chiu K, Oliner KS, Damore MA, Arnold GE, Sohn W, Chirmule N, Goyal L, Banfield C, Chung JB.

Arthritis Rheumatol. 2015 Oct;67(10):2713-22. doi: 10.1002/art.39248.


Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus.

Chen P, Vu T, Narayanan A, Sohn W, Wang J, Boedigheimer M, Welcher AA, Sullivan B, Martin DA, Ruixo JJ, Ma P.

Pharm Res. 2015 Feb;32(2):640-53. doi: 10.1007/s11095-014-1492-2. Epub 2014 Sep 12.


Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.

Russell CB, Rand H, Bigler J, Kerkof K, Timour M, Bautista E, Krueger JG, Salinger DH, Welcher AA, Martin DA.

J Immunol. 2014 Apr 15;192(8):3828-36. doi: 10.4049/jimmunol.1301737. Epub 2014 Mar 19.


Evidence for endotoxin contamination in plastic Na+-heparin blood collection tube lots.

Newhall KJ, Diemer GS, Leshinsky N, Kerkof K, Chute HT, Russell CB, Rees W, Welcher AA, Patterson SD, Means GD.

Clin Chem. 2010 Sep;56(9):1483-91. doi: 10.1373/clinchem.2006.144618. Epub 2010 Jul 27.


Maximizing the sensitivity and reliability of peptide identification in large-scale proteomic experiments by harnessing multiple search engines.

Yu W, Taylor JA, Davis MT, Bonilla LE, Lee KA, Auger PL, Farnsworth CC, Welcher AA, Patterson SD.

Proteomics. 2010 Mar;10(6):1172-89. doi: 10.1002/pmic.200900074.


Inducible costimulator expression regulates the magnitude of Th2-mediated airway inflammation by regulating the number of Th2 cells.

Clay BS, Shilling RA, Bandukwala HS, Moore TV, Cannon JL, Welcher AA, Weinstock JV, Sperling AI.

PLoS One. 2009 Nov 4;4(11):e7525. doi: 10.1371/journal.pone.0007525.


CD28 and ICOS play complementary non-overlapping roles in the development of Th2 immunity in vivo.

Shilling RA, Clay BS, Tesciuba AG, Berry EL, Lu T, Moore TV, Bandukwala HS, Tong J, Weinstock JV, Flavell RA, Horan T, Yoshinaga SK, Welcher AA, Cannon JL, Sperling AI.

Cell Immunol. 2009;259(2):177-84. doi: 10.1016/j.cellimm.2009.06.013. Epub 2009 Jul 10.


ICOS costimulation expands Th2 immunity by augmenting migration of lymphocytes to draining lymph nodes.

Tesciuba AG, Shilling RA, Agarwal MD, Bandukwala HS, Clay BS, Moore TV, Weinstock JV, Welcher AA, Sperling AI.

J Immunol. 2008 Jul 15;181(2):1019-24.


Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.

DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Chai L, Chaffee SC, Deak HL, Epstein LF, Faust T, Gallant P, Gore A, Gu Y, Henkle B, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, Zhao H, Zhu L, Zhu X.

J Med Chem. 2008 Mar 27;51(6):1681-94. doi: 10.1021/jm7010996. Epub 2008 Mar 6.


Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.

Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG.

J Med Chem. 2008 Mar 27;51(6):1637-48. doi: 10.1021/jm701095m. Epub 2008 Feb 16.


ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells.

Bossaller L, Burger J, Draeger R, Grimbacher B, Knoth R, Plebani A, Durandy A, Baumann U, Schlesier M, Welcher AA, Peter HH, Warnatz K.

J Immunol. 2006 Oct 1;177(7):4927-32.


Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.

DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cee VJ, Chai L, Deak HL, Epstein LF, Faust T, Gallant P, Geuns-Meyer SD, Gore A, Gu Y, Henkle B, Hodous BL, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, Masse CE, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, White RD, Zhao H, Zhu L, Zhu X.

J Med Chem. 2006 Sep 21;49(19):5671-86.


Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.

Martin MW, Newcomb J, Nunes JJ, McGowan DC, Armistead DM, Boucher C, Buchanan JL, Buckner W, Chai L, Elbaum D, Epstein LF, Faust T, Flynn S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Lee JH, Metz D, Middleton S, Mohn D, Morgenstern K, Morrison MJ, Novak PM, Oliveira-dos-Santos A, Powers D, Rose P, Schneider S, Sell S, Tudor Y, Turci SM, Welcher AA, White RD, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Amouzegh P, Ermann M, Jenkins J, Johnston D, Napier S, Power E.

J Med Chem. 2006 Aug 10;49(16):4981-91.


Regulation of T cell activation and tolerance by PDL2.

Zhang Y, Chung Y, Bishop C, Daugherty B, Chute H, Holst P, Kurahara C, Lott F, Sun N, Welcher AA, Dong C.

Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11695-700. Epub 2006 Jul 24.


CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues.

Kraus DM, Elliott GS, Chute H, Horan T, Pfenninger KH, Sanford SD, Foster S, Scully S, Welcher AA, Holers VM.

J Immunol. 2006 Apr 1;176(7):4419-30.


Paradoxical role of programmed death-1 ligand 2 in Th2 immune responses in vitro and in a mouse asthma model in vivo.

Oflazoglu E, Swart DA, Anders-Bartholo P, Jessup HK, Norment AM, Lawrence WA, Brasel K, Tocker JE, Horan T, Welcher AA, Fitzpatrick DR.

Eur J Immunol. 2004 Dec;34(12):3326-36.


Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra.

Knott C, Stern G, Kingsbury A, Welcher AA, Wilkin GP.

Parkinsonism Relat Disord. 2002 Jun;8(5):329-41.


Inducible CO-stimulator molecule, a candidate gene for defective isotype switching, is normal in patients with hyper-IgM syndrome of unknown molecular diagnosis.

Lee WI, Zhu Q, Gambineri E, Jin Y, Welcher AA, Ochs HD.

J Allergy Clin Immunol. 2003 Nov;112(5):958-64.


Endogenous brain-derived neurotrophic factor and neurotrophin-3 antagonistically regulate survival of axotomized corticospinal neurons in vivo.

Giehl KM, Röhrig S, Bonatz H, Gutjahr M, Leiner B, Bartke I, Yan Q, Reichardt LF, Backus C, Welcher AA, Dethleffsen K, Mestres P, Meyer M.

J Neurosci. 2001 May 15;21(10):3492-502.


Chicken macrophage stimulating protein is a ligand of the receptor protein-tyrosine kinase Sea.

Wahl RC, Hsu RY, Huff JL, Jelinek MA, Chen K, Courchesne P, Patterson SD, Parsons JT, Welcher AA.

J Biol Chem. 1999 Sep 10;274(37):26361-8.


Biochemical, biophysical, and pharmacological characterization of bacterially expressed human agouti-related protein.

Rosenfeld RD, Zeni L, Welcher AA, Narhi LO, Hale C, Marasco J, Delaney J, Gleason T, Philo JS, Katta V, Hui J, Baumgartner J, Graham M, Stark KL, Karbon W.

Biochemistry. 1998 Nov 17;37(46):16041-52.


Human leptin receptor. Determination of disulfide structure and N-glycosylation sites of the extracellular domain.

Haniu M, Arakawa T, Bures EJ, Young Y, Hui JO, Rohde MF, Welcher AA, Horan T.

J Biol Chem. 1998 Oct 30;273(44):28691-9.


Expression of growth factors and their receptors in the postnatal rat cochlea.

Malgrange B, Rogister B, Lefebvre PP, Mazy-Servais C, Welcher AA, Bonnet C, Hsu RY, Rigo JM, Van De Water TR, Moonen G.

Neurochem Res. 1998 Aug;23(8):1133-8.


Neural membrane protein 35 (NMP35): a novel member of a gene family which is highly expressed in the adult nervous system.

Schweitzer B, Taylor V, Welcher AA, McClelland M, Suter U.

Mol Cell Neurosci. 1998 Aug;11(5-6):260-73.


Cloning and characterization of a specific receptor for mouse oncostatin M.

Lindberg RA, Juan TS, Welcher AA, Sun Y, Cupples R, Guthrie B, Fletcher FA.

Mol Cell Biol. 1998 Jun;18(6):3357-67.


Neurotrophins and time: different roles for TrkB signaling in hippocampal long-term potentiation.

Kang H, Welcher AA, Shelton D, Schuman EM.

Neuron. 1997 Sep;19(3):653-64.


Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.

Haniu M, Montestruque S, Bures EJ, Talvenheimo J, Toso R, Lewis-Sandy S, Welcher AA, Rohde MF.

J Biol Chem. 1997 Oct 3;272(40):25296-303.


BDNF/NT4-5 receptor TrkB and cadherin participate in cell-cell adhesion.

Zhou H, Welcher AA, Shooter EM.

J Neurosci Res. 1997 Aug 1;49(3):281-91.


Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system.

Yan Q, Rosenfeld RD, Matheson CR, Hawkins N, Lopez OT, Bennett L, Welcher AA.

Neuroscience. 1997 May;78(2):431-48.


Immunocytochemical localization of TrkB in the central nervous system of the adult rat.

Yan Q, Radeke MJ, Matheson CR, Talvenheimo J, Welcher AA, Feinstein SC.

J Comp Neurol. 1997 Feb 3;378(1):135-57. Erratum in: J Comp Neurol 1997 Jun 16;382(4):546-7.


Changing patterns of expression and subcellular localization of TrkB in the developing visual system.

Cabelli RJ, Allendoerfer KL, Radeke MJ, Welcher AA, Feinstein SC, Shatz CJ.

J Neurosci. 1996 Dec 15;16(24):7965-80.


Identification and characterization of a cDNA and the structural gene encoding the mouse epithelial membrane protein-1.

Lobsiger CS, Magyar JP, Taylor V, Wulf P, Welcher AA, Program AE, Suter U.

Genomics. 1996 Sep 15;36(3):379-87.


Fatty acid binding protein is induced in neurons of the dorsal root ganglia after peripheral nerve injury.

De León M, Welcher AA, Nahin RH, Liu Y, Ruda MA, Shooter EM, Molina CA.

J Neurosci Res. 1996 May 1;44(3):283-92.


Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family.

Taylor V, Welcher AA, Program AE, Suter U.

J Biol Chem. 1995 Dec 1;270(48):28824-33.


Purification and identification of brain-derived neurotrophic factor from human serum.

Rosenfeld RD, Zeni L, Haniu M, Talvenheimo J, Radka SF, Bennett L, Miller JA, Welcher AA.

Protein Expr Purif. 1995 Aug;6(4):465-71.


cDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases.

Fox GM, Holst PL, Chute HT, Lindberg RA, Janssen AM, Basu R, Welcher AA.

Oncogene. 1995 Mar 2;10(5):897-905.


The molecular basis of the neuropathies of mouse and human.

Snipes GJ, Suter U, Welcher AA, Shooter EM.

Prog Brain Res. 1995;105:319-25. Review. No abstract available.


Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters.

Suter U, Snipes GJ, Schoener-Scott R, Welcher AA, Pareek S, Lupski JR, Murphy RA, Shooter EM, Patel PI.

J Biol Chem. 1994 Oct 14;269(41):25795-808.


B61 is a ligand for the ECK receptor protein-tyrosine kinase.

Bartley TD, Hunt RW, Welcher AA, Boyle WJ, Parker VP, Lindberg RA, Lu HS, Colombero AM, Elliott RL, Guthrie BA, et al.

Nature. 1994 Apr 7;368(6471):558-60.


Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the PMP22 gene.

Roa BB, Garcia CA, Suter U, Kulpa DA, Wise CA, Mueller J, Welcher AA, Snipes GJ, Shooter EM, Patel PI, Lupski JR.

N Engl J Med. 1993 Jul 8;329(2):96-101.


Detection and processing of peripheral myelin protein PMP22 in cultured Schwann cells.

Pareek S, Suter U, Snipes GJ, Welcher AA, Shooter EM, Murphy RA.

J Biol Chem. 1993 May 15;268(14):10372-9.


The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A.

Patel PI, Roa BB, Welcher AA, Schoener-Scott R, Trask BJ, Pentao L, Snipes GJ, Garcia CA, Francke U, Shooter EM, Lupski JR, Suter U.

Nat Genet. 1992 Jun;1(3):159-65.


A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse.

Suter U, Moskow JJ, Welcher AA, Snipes GJ, Kosaras B, Sidman RL, Buchberg AM, Shooter EM.

Proc Natl Acad Sci U S A. 1992 May 15;89(10):4382-6.


Supplemental Content

Loading ...
Support Center